Demonstrate that educating employers on ART practices, clinical outcomes and technology advances can increase access to care and utilization of ART by employees. Furthermore, will adoption of coverage by informed employers increase the use of elective single embryo transfer (eSET) and significantly reduce multiple gestations as a result of IVF treatment? A retrospective analysis with historical company and national data. The funded ART benefit offered by a number of large, self insured employers was examined and analyzed to assess the associated expense to the employer for employees utilizing ART. The employers were informed and educated on innovations within the ART field. Beginning in January 2016 employees in two companies began utilizing a new fully funded ART benefit that included embryo selection and eSET. Historical company data on the cost of high order multiples from ART treatment in 2014 was compared to expected data based on eSET in the fully funded program. In addition, the percentage of employees utilizing the benefit was compared to national averages in multiple states in the U.S. In Q1 2016, 299 ART treatments were initiated (248 IVF and 51 IUI) for a predicted annual utilization rate of approximately 1%. When compared to utilization rates nationally and in the home state of the employers using 2013 SART data (0.25 %), the utilization thus far is four times higher. Nationally, in 2013, eSET was performed in 23.6 % of patients of all ages. Thus far in Q1 2016, with increasing employee awareness, the monthly percentage of eSET cycles reached 80% with an overall pregnancy rate of 56.9 % (FHB+). With continued education on the advantages of eSET we expect the percentage of cycles with transfer of one embryo to continue to increase. At the end of Q1 there were no multiple gestations reported in this data. NThe utilization rate for the two companies is 4 times higher than the national average and double the utilization rates seen in states with an ART mandate (0.48%). This data clearly shows that an employer offering a fertility benefit will increase utilization of IVF in the U.S. In SART 2013 data the average number of embryos transferred was 1.8 in women < 35. Given that the medical costs associated with multiple gestations are at least 5-20 times higher than singletons, the use of eSET to increase the percentage of singleton births will result in a predicted savings of approximately $4 Million/employer based on our analysis of claims data and the Truven Health Analytics database. By engaging and educating employers with regards to the need for ART coverage and the medical and financial burdens associated with multiple gestations, it is anticipated that more than the current 25% of employers, which provide an ART benefit, will fund comprehensive coverage for IVF treatments in the coming years.